A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.434, issue.7037, pp.1144-1148, 2005. ,
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Cancer Genome P, vol.365, issue.9464, pp.71142-71151, 2005. ,
A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, vol.352, issue.17, pp.1779-1790, 2005. ,
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, issue.4, pp.387-397, 2005. ,
The JAK2V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera, Blood, vol.108, issue.6, pp.1865-1867, 2006. ,
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders, Blood, vol.107, issue.9, pp.3676-3682, 2006. ,
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-3072, 2008. ,
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study, Leukemia, vol.27, issue.10, pp.2032-2039, 2013. ,
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera, Leuk Ann Hematol Lymphoma, vol.57, pp.1-7, 2015. ,
British Committee for Standards in H (2013) Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations, Br J Haematol, vol.160, issue.1, pp.25-34 ,
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study, Haematologica, vol.94, issue.1, pp.38-45, 2009. ,
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: a study involving a consortium of 19 Italian laboratories, Oncotarget, vol.8, pp.32608-32617, 1920. ,
The JAK2 V617F mutation involves B-and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders, Br J Haematol, vol.136, issue.5, pp.745-751, 2007. ,
An Italian program of external quality control for quantitative assays based on real-time PCR with TaqMan probes, Clin Chem Lab Med: CCLM / FESCC, vol.43, issue.5, pp.542-548, 2005. ,
Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F), Leukemia, vol.21, issue.5, pp.1128-1130, 2007. ,
International Randomised Study of Interferon versus STISG (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia, N Engl J Med, vol.349, issue.15, pp.1423-1432 ,
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, vol.108, issue.1, pp.28-37, 2006. ,
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA, Blood, vol.116, issue.22, pp.111-117, 2010. ,
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by realtime quantitative PCR, Leukemia, vol.29, issue.2, pp.369-376, 2015. ,
Collaborative study to evaluate the proposed WHO 1st International Reference Panel for Genomic JAK2 V617F, 2016. ,